The risk of dementia is increased in 50-year-olds with blood pressure ≥130 mm Hg, which is below the current threshold for hypertension.
Phase 3 clinical trials for lanabecestat (Eli Lilly and AstraZeneca), an investigational Alzheimer disease treatment, are being discontinued for futility.
The lifetime risks of Alzheimer disease dementia vary considerably by age, gender, and the preclinical or clinical disease state.
There is a reduced risk for dementia for older Chinese adults actively participating in intellectual activities.
Public health strategies for preventing dementia should target socioeconomic gaps to reduce health disparities and protect the disadvantaged.
The researchers encouraged clinicians not to rely solely on medication to treat midlife anxiety, as benzodiazepines have been shown to increase mortality in certain groups; they pointed to talk therapy, meditation, and mindfulness-based interventions as possible considerations.
Multimarker inflammatory biosignatures are expected to facilitate diagnosis and predict treatment outcomes for various central nervous system disorders, particularly Alzheimer disease and major depressive disorder.
Clinicians should take depression into careful consideration when treating patients with Alzheimer dementia, as the two conditions combined may predispose patients to cardiovascular disease more than either condition alone.
These findings indicate that anxiety may be a risk factor for late-life dementia, excluding anxiety that is related to prodromal cognitive decline.
These results suggest that antipsychotic exposure has no impact on relative mortality.
The use of certain anticholinergic drugs may increase the risk of future dementia.
Using hearing aids may slow cognitive decline in later life.
These data support the importance of TBI preventative measures and proper management strategies for subsequent dementia.
The findings also suggested that more a more recent diagnosis of psychosis was a greater predictor of the development of dementia, as opposed to cases where patients had been living with psychotic disorder diagnoses for 10 years or more.
Patients with a phonemic advantage at baseline should be followed more closely with a higher index of suspicion for progression to Alzheimer disease.
Researchers concluded that the partnership did not accelerate the overall decline in antipsychotic medication use among study participants.
A study was conducted to assess potential beneficial effects of a lifestyle intervention program on cognition in carriers of the APOE ε4 allele.
Spouses who are affected by dementia may benefit from an at-home dyadic, relationship-focused psychoeducational intervention.
These findings support the recognition of alcohol use disorders as a major risk factor for all dementia types.
There are a handful of biomarkers that offer potential value for predicting the risk for development of MCI symptoms from AD symptoms.
Positive beliefs about age may protect against dementia.
Patients randomly assigned to the intervention experienced a statistically significant improvement in quality of life, agitation, and overall neuropsychiatric symptoms.
Depressive symptoms and apathy were independently associated with incident dementia in community-dwelling older adults.
Michael Thase, MD, comments on the potential for lithium in drinking water as a psychiatric prophylactic agent.
Increased triglyceride levels at midlife are predictive of the presence of β-amyloid 20 years later in cognitively healthy individuals.
There is a greater risk for cognitive decline and impairment in elderly patients who experience age-related hearing loss.
There is limited evidence for the benefits of different interventions to prevent late-life dementia.
Dementia risk was associated with neither proton pump inhibitor exposure nor duration of use.
40% of people with dementia are still driving.
Low and high serum magnesium levels were shown to be associated with increased risk of all-cause dementia.
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Should Physicians Treat Family and Friends? Three Experts Weigh In
- Transference in the Age of #MeToo: What Counts as Harassment From a Patient?
- Dialectical Behavior Therapy Effective in Reducing Suicide Attempts, Self-Harm in Adolescents
- Influence of Psychostimulants on BMI and Height in Youth With ADHD
- Medication Adherence Predictors in Patients With Severe Psychiatric Disorders
- Court-Mandated Substance Abuse Treatment: Exploring the Ethics and Efficacy
- ADHD Treatments
- Esketamine Nasal Spray: A New Treatment Possibility for Treatment-Resistant Depression
- Pharmacogenetics in Psychiatry: Promising Developments and Potential Pitfalls
- Substance Abuse and Primary Psychosis: A Closer Look
- Functional Restoration for Chronic Pain and Depression in the Elderly: Pharmacotherapy and Beyond
- Efficacy of Long-Acting Injectable Antipsychotics vs Oral Antipsychotics
- Older Age Associated With Worse Major Depressive Disorder Outcomes
- Preoperative Psychiatric Diagnoses Not Associated With Bariatric Surgery Outcomes
- Medical Clearance of Psych Patients in the ED: Consensus Recommendations